Dr. Tulika Ranjan is a renowned neuro-oncologist with the Cancer Institute at Tampa General Hospital. She has a wealth of experience in treating adult primary brain and spinal cord tumors and has conducted groundbreaking research on new therapies for treating glioblastoma (GBM).
Prior to joining Tampa General Hospital, Dr. Ranjan was the director of the Allegheny Health Network (AHN) adult neuro-oncology program that specialized in advanced modalities such as laser interstitial thermal therapy and cancer stem cell chemo-sensitivity testing. She also served as chairperson for AHN Cancer Institute Neurologic-Oncology disease site leadership team.
Before joining AHN in 2015, Dr. Ranjan was part of the collaborative clinical research team at Duke University’s Preston Robert Tisch Brain Tumor Center that developed a novel therapy using the polio virus to treat GMB, a highly aggressive form of brain cancer.
Dr. Ranjan’s prominent clinical trials include “Chemo ID for GBM,” which was a multicenter trial run at the national level. Her Executive General Management program education from Harvard University, further supports innovations and cost-effective management in the health care field.
Neuro-Oncology, American Board of Psychiatry and Neurology
Brain cancer • Brain metastases • Glioblastoma • Leptomeningeal disease • Primary central nervous system (CNS) lymphoma
Ependymoma • Low-grade glial tumor • Meningioma • Schwannoma
Chemotherapy • Clinical trials • Immunotherapy • Ommaya/intrathecal treatment • Optune device • Targeted therapy
Sri Krishna Medical College (India)
Neurology and Medicine
Rutgers University (Newark, N.J.)
Memorial Sloan Kettering Cancer Center (New York City, N.Y.)
GENERAL MANAGEMENT PROGRAM
Harvard Business School (HBS) (Boston, Mass.)